Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: Application to active immunotherapy

Experimental Hematology

Volumn 36, Issue 3, 2008, Pages 329-339

  Royer, Pierre Joseph ^a,b   Bougras, Gwenola ^a,b   Ebstein, Frederic ^a,b   Leveque, Lucie ^a,b   Tanguy Royer, Severine ^a,b   Simon, Thomas ^a,b   Juge Morineau, Nadine ^c   Chevallier, Patrice ^a,c   Harousseau, Jean Luc ^c   Gregoire, Marc ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; IDARUBICIN; LOMUSTINE; METHOTREXATE; PURENITOL; RETINOIC ACID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CELL CYCLE; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, CCR7; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 39149103376     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.11.001     Document Type: Article

References (37)

1. Lowenberg B., Griffin J.D., and Tallman M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Program) (2003) 82-101
2. Smith M., Barnett M., Bassan R., et al. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50 (2004) 197-222
3. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 21 (2003) 873-886
4. Imoto S., Murayama T., Gomyo H., et al. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 26 (2000) 809-810
5. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 (2000) 1018-1023
6. Roddie H., Klammer M., Thomas C., et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 133 (2006) 152-157
7. Charbonnier A., Gaugler B., Sainty D., Lafage-Pochitaloff M., and Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol 29 (1999) 2567-2578
8. Choudhury B.A., Liang J.C., Thomas E.K., et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93 (1999) 780-786
9. Harrison B.D., Adams J.A., Briggs M., Brereton M.L., and Yin J.A. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 97 (2001) 2764-2771
10. Kohler T., Plettig R., Wetzstein W., et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 18 (2000) 139-147
11. Panoskaltsis N., Belanger T.J., Liesveld J.L., and Abboud C.N. Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. Leuk Res 26 (2002) 191-201
12. Panoskaltsis N. Dendritic cells in MDS and AML-cause, effect or solution to the immune pathogenesis of disease?. Leukemia 19 (2005) 354-357
13. Spisek R., Chevallier P., Morineau N., et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 62 (2002) 2861-2868
14. Cignetti A., Vallario A., Roato I., et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol 173 (2004) 2855-2865
15. Mohty M., Olive D., and Gaugler B. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia 16 (2002) 2197-2204
16. Spisek R., Bretaudeau L., Barbieux I., Meflah K., and Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 50 (2001) 417-427
17. Scandella E., Men Y., Gillessen S., Forster R., and Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100 (2002) 1354-1361
18. Schui D.K., Singh L., Schneider B., et al. Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts. Leuk Res 26 (2002) 383-389
19. Gregoire M., Ligeza-Poisson C., Juge-Morineau N., and Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 21 (2003) 791-794
20. Berger T.G., Feuerstein B., Strasser E., et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 268 (2002) 131-140
21. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 (2006) 17-58
22. Luft T., Jefford M., Luetjens P., et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100 (2002) 1362-1372
23. Bocchia M., Bronte V., Colombo M.P., et al. Antitumor vaccination: where we stand. Haematologica 85 (2000) 1172-1206
24. Bruserud O., and Wendelboe O. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?. Exp Opin Biol Ther 1 (2001) 1005-1016
25. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 10 (2004) 475-480
26. Curti A., Isidori A., Ferri E., et al. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma 45 (2004) 1419-1428
27. Schutt P., Buttkereit U., Brandhorst D., et al. In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. Cancer Immunol Immunother 54 (2005) 506-512
28. Syme R.M., Duggan P., Stewart D., and Gluck S. Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors. J Hematother Stem Cell Res 10 (2001) 621-630
29. Yi Q., Desikan R., Barlogie B., and Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 117 (2002) 297-305
30. Zheng C., Pisa P., Stromberg O., Blennow E., and Hansson M. Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia. Med Oncol 17 (2000) 270-278
31. Berger T.G., Strasser E., Smith R., et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 298 (2005) 61-72
32. Royer P.J., Tanguy-Royer S., Ebstein F., et al. Culture medium and protein supplementation in the generation and maturation of dendritic cells. Scand J Immunol 63 (2006) 401-409
33. Mackall C.L. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist 4 (1999) 370-378
34. Bertho N., Adamski H., Toujas L., et al. Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction. Blood 106 (2005) 1734-1741
35. Hu W., Mathey E., Hartung H.P., and Kieseier B.C. Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 61 (2003) 1774-1779
36. Legler D.F., Krause P., Scandella E., Singer E., and Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176 (2006) 966-973
37. Wendelbo O., Nesthus I., Sjo M., et al. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 53 (2004) 740-747